Loading
POLD2 (DNA polymerase delta subunit 2) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.
Accessory component of both the DNA polymerase delta complex and the DNA polymerase zeta complex. As a component of the trimeric and tetrameric DNA polymerase delta complexes (Pol-delta3 and Pol-delta4, respectively), plays a role in high fidelity genome replication, including in lagging strand synthesis, and repair. Pol-delta3 and Pol-delta4 are characterised by the absence or the presence of POLD4.
Open Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.73, genetic association 0.00, clinical 0.99).
In plain words · POLD2 (DNA polymerase delta subunit 2) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.
POLD2 (DNA polymerase delta subunit 2) is a gene. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Non-Hodgkin lymphoma, Lung cancer and 5 more.
Accessory component of both the DNA polymerase delta complex and the DNA polymerase zeta complex.
No product in this corpus aims at POLD2 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA lists POLD2 among essential proteins and finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA POLD2: RNA low tissue specificity; high antibody staining in 23 normal tissues; highest cancer staining stomach cancer (6 of 10 high). Distribution: 6 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Lymphoma, Lung cancer (all types), Myeloid neoplasms, Breast cancer (all types), Ovarian cancer); Open Targets associates it with 10 specific cancer types at or above 0.5 (acute lymphoblastic leukemia, acute myeloid leukemia, non-small cell lung carcinoma, B-cell chronic lymphocytic leukemia, exocrine pancreatic carcinoma, ovarian carcinoma and more). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas POLD2 tissue; Open Targets ENSG00000106628 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Zhang et al, Genomics, 1995, "Cloning of the cDNAs for the small subunits of bovine and human DNA polymerase delta and chromosomal location of the human gene (POLD2)". Source.
Sources: HGNC HGNC:9176 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P49005 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000106628 (association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.60, ovarian cancer 0.58, acute myeloid leukaemia 0.59, acute lymphoblastic leukaemia 0.60, B-cell chronic lymphocytic leukaemia 0.59, non-Hodgkin lymphoma 0.60 (GraphQL API, CC0))
Accessory component of both the DNA polymerase delta complex and the DNA polymerase zeta complex. As a component of the trimeric and tetrameric DNA polymerase delta complexes (Pol-delta3 and Pol-delta4, respectively), plays a role in high fidelity genome replication, including in lagging strand synthesis, and repair. Pol-delta3 and Pol-delta4 are characterised by the absence or the presence of POLD4. They exhibit differences in catalytic activity. Most notably, Pol-delta3 shows higher proofreading activity than Pol-delta4. Although both Pol-delta3 and Pol-delta4 process Okazaki fragments in vitro, Pol-delta3 may also be better suited to fulfill this task, exhibiting near-absence of strand displacement activity compared to Pol-delta4 and stalling on encounter with the 5'-blocking oligonucleotides. Location: Nucleus (UniProt). Locus 7p13 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adrenal gland, Endometrium, Gallbladder, Soft tissue, Thyroid gland.
Medium only: endometrial cancer, prostate cancer.
HPA POLD2 tissue · HPA POLD2 pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"POLD2" OR ABSTRACT:"POLD2" OR TITLE:"DNA polymerase delta 2, accessory subunit" OR ABSTRACT:"DNA polymerase delta 2, accessory subunit" OR TITLE:"DNA polymerase delta subunit 2" OR ABSTRACT:"DNA polymerase delta subunit 2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about POLD2, not a curated reading list.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.
Shares Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Acute lymphoblastic leukaemia.